The growth of the EPS is critical in understanding the current valuation of Nemaura Medical. I will do my best to analyze this stock, but there is limited information, therefore please check back later by doing a search here or going to the tag page for the stock symbol NMRD here. Growth in EPS is an important measure of administration performance because it shows how much money Nemaura Medical is making for it’s investors or shareholders.



Nemaura Medical is part of the healthcare sector and trades as part of the medical devices industry. The company CEO is Dewan Fazlul Hoque Chowdhury. Nemaura Medical Inc owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices.

Previous Intraday Performance:

The NMRD shares had a previous change of -0.10% which opened at 0.95 and closed at 0.93. It moved to an intraday high of 1.00 and a low of 0.91.

SeekingAlpha:  Healthcare & Tech leads midday movers

Historical Performance:

Over the last five trading days, NMRD shares returned 2.57% and in the past 30 trading days it returned -50.10%. Over three months, it changed -58.75%. In one year it has changed -81.80% and within that year its 52-week high was 6.80 and its 52-week low was 0.80. NMRD stock is 16.01% above its 52 Week Low.

Our calculations result in a 200 day moving average of 2.55 and a 50 day moving average of 1.57. Right now, NMRD stock is trading -63.66% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Nemaura Medical prices $2.5M stock offering; shares down 42% premarket

Liquidity:

The company has a market cap of $192.4m with 207.3m shares outstanding and a float of 88.6m shares. Trading volume was 53,598 shares and has experienced an average volume of 138,129 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Nemaura Medical was -0.01 which ended on 31st of March 2018.

Indicators Also to Watch:

Based on the latest filings, there is 57.90% of insider ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be -0.06



SeekingAlpha:  RCII and ITCI among premarket losers

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -83.75%, return on assets is -51.36% and price-to-book is 93.55.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here